While AZ is eyeing overseas expansion with its new investment, J&J has embarked on a reshoring drive with a pledge to invest ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting ...

At the show, Synchron demonstrated how its Stentrode BCI, a stent-like device implanted via the neck into blood vessels near ...

It has already been speculated that AstraZeneca's termination of a plan to invest £450 million in a new vaccine manufacturing ...

Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

Among the leading biotech organisations, innovators and solution providers joining the show, are Discovery Park, Thistle ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

The Innovation in Psychosis Therapeutics Summit is the leading industry event driving the next generation of psychosis drug ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

February saw several changes on boards at biotechs, bringing a diverse wealth of experience to support these companies. Read ...